9.85
+9.44%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Capricor Therapeutics
From its filings with the US Securities and Exchange Commission
Capricor Therapeutics is based in San Diego, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CAPR. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $0 and a net loss of $105.0m. At that date it held total assets of $355.9m and shareholders' equity of $305.8m.
Capricor Therapeutics, Inc. is a biotechnology company focused on the development and potential commercialization of cell and exosome-based therapeutics for the treatment of Duchenne muscular dystrophy (“DMD”), a rare genetic disorder characterized by progressive muscle degeneration and premature death, as well as other diseases with significant unmet medical need. Since our inception, we have devoted substantial resources to the development of our lead product candidate, Deramiocel, a cell therapy designed to address the cardiac and skeletal muscle complications associated with DMD, as well as to advancing our exosome-based platform, developing manufacturing capabilities and supporting our research and development activities. Our Biologics License Application (“BLA”) for Deramiocel for the treatment of DMD is currently under review by the U.S. Food and Drug Administration (“FDA”), with a Prescription Drug User Fee Act (“PDUFA”) target action date of August 22, 2026, for potential approval in the United States. We currently have no products approved for commercial sale. Our ability to generate product revenue and achieve profitability will depend on the successful development, regulatory approval and commercialization of Deramiocel and any other product candidates we may develop. If approved, we intend to commercialize Deramiocel in the United States and may seek commercialization through strategic partners in other select international markets.
Quoted from its 10-K, filed 17 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 4 Jun 2002
- Employees
- 231
- Website
- capricor.com ↗
- Head office
- 10865 ROAD TO THE CURE, SAN DIEGO, CA, 92121
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Frank LitvackExecutive Chairman of the Board, since 2009$982,400
- Dr. Linda MarbanPresident, Chief Executive Officer, Director, since 2013$1.5m
- Mr. Anthony BergmannChief Financial Officer$930,230
- Ms. Karen KrasneyExecutive Vice President, General Counsel$869,560
- Dr. Michael BinksChief Medical Officer
- Dr. Paul AuwaerterIndependent Director$156,853
- Mr. George DunbarIndependent Director$222,226
- Ms. Karimah Es SabarIndependent Director$203,476
- Dr. Philip GotwalsIndependent Director$157,064
- Mr. Michael KelliherIndependent Director$275,609
- Mr. David MusketIndependent Director$248,501
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 24
- Environment
- 22
- Social
- 23
- Governance
- 25
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Capricor Therapeutics Inc has several key strengths that contribute to its competitive advantage in the market. Firstly, the company possesses a strong proprietary platform technology, which enables the development of novel therapeutics for the treatment of various diseases. This technology provides Capricor with a unique market position and the potential for significant revenue growth. Additionally, Capricor has a talented and experienced management team with expertise in both scientific research and business development. This leadership team is capable of guiding the company through its various stages of growth and ensuring the successful commercialization of its products. Furthermore, Capricor has built strong collaborative partnerships with leading academic institutions and pharmaceutical companies. These partnerships provide access to valuable resources, expertise, and potential distribution channels, enhancing the company's research capabilities and market reach. Lastly, Capricor has a robust intellectual property portfolio, including patents and licenses. This strengthens the company's position in the market, protects its innovative technologies, and creates barriers to entry for potential competitors.
Weaknesses
- Despite its strengths, Capricor Therapeutics Inc also faces certain weaknesses that can hinder its growth and performance. One notable weakness is the company's heavy reliance on a limited number of product candidates. The failure of any of these candidates during clinical trials or regulatory approval processes could significantly impact Capricor's financial stability and future prospects. Moreover, as a relatively small biopharmaceutical company, Capricor may encounter challenges in terms of access to capital. This could restrict the company's ability to fund its research and development initiatives or expand its operations. Additionally, the dependence on strategic partnerships can be a double-edged sword. While these collaborations offer valuable benefits, they also introduce potential risks, including the loss of control over certain aspects of the business or conflicts of interest with partners. Lastly, Capricor operates in a highly competitive and regulated industry. The company may face challenges in successfully navigating the complex regulatory landscape and effectively differentiating its products from those of competitors.
Opportunities
- Capricor Therapeutics Inc has several opportunities that it can capitalize on to drive future growth and success. Firstly, the increasing prevalence of chronic diseases presents a significant market opportunity for Capricor's therapeutic solutions. The rising global burden of diseases such as heart failure and Duchenne muscular dystrophy creates a growing demand for effective treatment options, which Capricor can address with its innovative therapies. Additionally, advancements in technology, such as gene editing and cell-based therapies, offer new avenues for the development of cutting-edge treatments. Capricor can leverage these technologies to further enhance its product pipeline and create differentiated offerings. Furthermore, the expanding global healthcare market, especially in emerging economies, provides Capricor with potential opportunities for geographic expansion and increased market penetration. Lastly, the growing focus on personalized medicine and precision therapeutics is a promising trend for Capricor. By developing targeted therapies that address individual patient needs, the company can gain a competitive advantage in the market.
Threats
- Capricor Therapeutics Inc faces several threats that could pose challenges to its growth and profitability. Firstly, the biopharmaceutical industry is subject to stringent regulatory requirements and compliance standards. Changes in regulations, delays in approvals, or failure to meet regulatory expectations can significantly impact Capricor's ability to bring products to market in a timely manner. Additionally, the company operates in a highly competitive market with numerous established pharmaceutical companies and emerging biotech firms. The presence of well-established competitors with extensive resources and established market positions can make it difficult for Capricor to capture significant market share. Moreover, the potential for intellectual property disputes and patent infringement claims poses a threat to Capricor's technological advancements and market exclusivity. Lastly, unforeseen events such as natural disasters, pandemics, or economic downturns can disrupt Capricor's operations, supply chain, and overall business performance.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.